FindTrial
Sign In

Vitamin B12 Injection

DRUG4 trials

Sponsors

Massachusetts General Hospital, Asan Medical Center, Cinnagen, Baermed

Conditions

Anemia in End-Stage Renal DiseaseBladder CancerDementiaFallopian Tube CancerModerate DementiaOvarian CancerPeritoneal CancerTransitional Cell Carcinoma

Phase 1

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
CompletedNCT01188876
Massachusetts General HospitalFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Start: 2010-08-31End: 2017-07-31Updated: 2018-01-19
Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment (Dementia)
Not yet recruitingNCT06632470
BaermedDementia, Moderate Dementia
Start: 2024-10-15End: 2025-10-01Target: 54Updated: 2024-10-09

Phase 3

Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy
NCT03193788
Asan Medical CenterBladder Cancer, Transitional Cell Carcinoma, Ureter Cancer
Start: 2017-01-31End: 2020-06-30Target: 74Updated: 2017-06-21
Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients
CompletedNCT03408639
CinnagenAnemia in End-Stage Renal Disease
Start: 2016-06-22End: 2017-07-19Updated: 2019-12-18

Related Papers

Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).
Journal of Clinical Oncology2024-01-291 citations
Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients
American Journal of Nephrology2018-01-0117 citations